{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T11:19:57Z","timestamp":1790680797524,"version":"4.1.0"},"reference-count":20,"publisher":"American Society of Hematology","issue":"3","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2005,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Among 2333 consecutive patients with myelofibrosis with myeloid metaplasia (MMM) seen at our institution, 91 fulfilled the World Health Organization (WHO) criteria for leukemic transformation (LT). All episodes of LT were myeloid in origin (acute myeloid leukemia [AML]) with all French-American-British (FAB) subtypes represented except M3; the most frequent subtypes were M7 (25.4%), M0 (22.4%), and M2 (17.9%). Cytogenetic studies during LT were available in 56 patients and revealed a clonal abnormality in 51 (91%): 30 patients had complex karyotype, 2 had core-binding factor gene lesions, and 18 had abnormalities of chromosome 5 or 7. Karyotypic evolution was documented in the majority of the patients in whom serial analysis was possible. In general, LT was fatal in 98% of the cases after a median of 2.6 months (range, 0-24.2 months). Twenty-four patients received AML-like induction chemotherapy that resulted in no complete remission: 41% reverted into chronic-phase disease and the incidence of treatment-related mortality was 33%. The remaining 67 patients received either supportive care alone (48 patients) or low-intensity chemotherapy (19 patients). Overall, survival was similarly poor in all 3 treatment categories. The outcome of LT in MMM with current therapies is dismal and either supportive care alone or appropriate clinical trials should be considered.<\/jats:p>","DOI":"10.1182\/blood-2004-07-2864","type":"journal-article","created":{"date-parts":[[2004,9,24]],"date-time":"2004-09-24T00:15:43Z","timestamp":1095984943000},"page":"973-977","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":341,"title":["Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases"],"prefix":"10.1182","volume":"105","author":[{"given":"Ruben A.","family":"Mesa","sequence":"first","affiliation":[{"name":"From the Divisions of Hematology and Internal Medicine, Hematopathology, and Laboratory Genetics and the Cancer Center Statistics Unit, Mayo Clinic, Rochester, MN."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chin-Yang","family":"Li","sequence":"additional","affiliation":[{"name":"From the Divisions of Hematology and Internal Medicine, Hematopathology, and Laboratory Genetics and the Cancer Center Statistics Unit, Mayo Clinic, Rochester, MN."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhett P.","family":"Ketterling","sequence":"additional","affiliation":[{"name":"From the Divisions of Hematology and Internal Medicine, Hematopathology, and Laboratory Genetics and the Cancer Center Statistics Unit, Mayo Clinic, Rochester, MN."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgene S.","family":"Schroeder","sequence":"additional","affiliation":[{"name":"From the Divisions of Hematology and Internal Medicine, Hematopathology, and Laboratory Genetics and the Cancer Center Statistics Unit, Mayo Clinic, Rochester, MN."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan A.","family":"Knudson","sequence":"additional","affiliation":[{"name":"From the Divisions of Hematology and Internal Medicine, Hematopathology, and Laboratory Genetics and the Cancer Center Statistics Unit, Mayo Clinic, Rochester, MN."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayalew","family":"Tefferi","sequence":"additional","affiliation":[{"name":"From the Divisions of Hematology and Internal Medicine, Hematopathology, and Laboratory Genetics and the Cancer Center Statistics Unit, Mayo Clinic, Rochester, MN."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2020021218061268800_REF1","unstructured":"Passamonti F, Malabarba L, Orlandi E, et al. Polycythemia vera in young patients: a study on the long-term risk of thrombosis, myelofibrosis and leukemia. Haematologica. 2003;88: 13-18."},{"key":"2020021218061268800_REF2","doi-asserted-by":"crossref","unstructured":"Cervantes F, Alvarez-Larran A, Talarn C, Gomez M, Montserrat E. Myelofibrosis with myeloid metaplasia following essential thrombocythaemia: actuarial probability, presenting characteristics and evolution in a series of 195 patients. Br J Haematol. 2002;118: 786-790.","DOI":"10.1046\/j.1365-2141.2002.03688.x"},{"key":"2020021218061268800_REF3","doi-asserted-by":"crossref","unstructured":"Tefferi A. Myelofibrosis with myeloid metaplasia. N Engl J Med. 2000;342: 1255-1265.","DOI":"10.1056\/NEJM200004273421706"},{"key":"2020021218061268800_REF4","doi-asserted-by":"crossref","unstructured":"Koch C, Li C, Mesa R, Tefferi A. Nonhepatosplenic extrameduallry hematopoiesis: associated diseases, pathology, clinical course, and treatment. Mayo Clin Proc. 2003;78: 1223-1233.","DOI":"10.4065\/78.10.1223"},{"key":"2020021218061268800_REF5","doi-asserted-by":"crossref","unstructured":"Cervantes F, Barosi G, Demory JL, et al. Myelofibrosis with myeloid metaplasia in young individuals: disease characteristics, prognostic factors and identification of risk groups. Br J Haematol. 1998;102: 684-690.","DOI":"10.1046\/j.1365-2141.1998.00833.x"},{"key":"2020021218061268800_REF6","doi-asserted-by":"crossref","unstructured":"Deeg HJ, Gooley TA, Flowers ME, et al. Allogeneic hematopoietic stem cell transplantation for myelofibrosis. Blood. 2003;102: 3912-3918.","DOI":"10.1182\/blood-2003-06-1856"},{"key":"2020021218061268800_REF7","doi-asserted-by":"crossref","unstructured":"Okamura T, Kinukawa N, Niho Y, Mizoguchi H. Primary chronic myelofibrosis: clinical and prognostic evaluation in 336 Japanese patients. Int J Hematol. 2001;73: 194-198.","DOI":"10.1007\/BF02981937"},{"key":"2020021218061268800_REF8","doi-asserted-by":"crossref","unstructured":"Cervantes F, Tassies D, Salgado C, Rovira M, Pereira A, Rozman C. Acute transformation in nonleukemic chronic myeloproliferative disorders: actuarial probability and main characteristics in a series of 218 patients. Acta Haematol. 1991;85: 124-127.","DOI":"10.1159\/000204873"},{"key":"2020021218061268800_REF9","doi-asserted-by":"crossref","unstructured":"Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100: 2292-2302.","DOI":"10.1182\/blood-2002-04-1199"},{"key":"2020021218061268800_REF10","doi-asserted-by":"crossref","unstructured":"Dupriez B, Morel P, Demory J, et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood. 1996;88: 1013-1018.","DOI":"10.1182\/blood.V88.3.1013.1013"},{"key":"2020021218061268800_REF11","doi-asserted-by":"crossref","unstructured":"Tefferi A, Mesa RA, Schroeder G, Hanson CA, Li CY, Dewald GW. Cytogenetic findings and their clinical relevance in myelofibrosis with myeloid metaplasia. Br J Haematol. 2001;113: 763-771.","DOI":"10.1046\/j.1365-2141.2001.02796.x"},{"key":"2020021218061268800_REF12","doi-asserted-by":"crossref","unstructured":"Mesa RA, Silverstein MN, Jacobsen SJ, Wollan PC, Tefferi A. Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: an Olmsted County Study, 1976-1995. Am J Hematol. 1999; 61: 10-15.","DOI":"10.1002\/(SICI)1096-8652(199905)61:1<10::AID-AJH3>3.0.CO;2-I"},{"key":"2020021218061268800_REF13","doi-asserted-by":"crossref","unstructured":"Baudard M, Beauchamp-Nicoud A, Delmer A, et al. Has the prognosis of adult patients with acute myeloid leukemia improved over years? A single institution experience of 784 consecutive patients over a 16-year period. Leukemia. 1999;13: 1481-1490.","DOI":"10.1038\/sj.leu.2401544"},{"key":"2020021218061268800_","doi-asserted-by":"crossref","unstructured":"Stasi R, Del Poeta G, Venditti A, et al. Analysis of treatment failure in patients with minimally differentiated acute myeloid leukemia (AML-M0). Blood. 1994;83: 1619-1625.","DOI":"10.1182\/blood.V83.6.1619.1619"},{"key":"2020021218061268800_REF15","unstructured":"Tallman MS, Neuberg D, Bennett JM, et al. Acute megakaryocytic leukemia: the Eastern Cooperative Oncology Group experience. Blood. 2000;96: 2405-2411."},{"key":"2020021218061268800_REF16","doi-asserted-by":"crossref","unstructured":"Tefferi A. Is hydroxyurea leukemogenic in essential thrombocythemia. Blood. 1998;92: 1459-1460.","DOI":"10.1182\/blood.V92.4.1459"},{"key":"2020021218061268800_REF17","unstructured":"Barosi G, Ambrosetti A, Centra A, et al. Splenectomy and risk of blast transformation in myelofibrosis with myeloid metaplasia: Italian Cooperative Study Group on Myeloid with Myeloid Metaplasia. Blood. 1998;91: 3630-3636."},{"key":"2020021218061268800_REF18","doi-asserted-by":"crossref","unstructured":"Tefferi A, Mesa RA, Nagorney DM, Schroeder G, Silverstein MN. Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients. Blood. 2000;95: 2226-2233.","DOI":"10.1182\/blood.V95.7.2226"},{"key":"2020021218061268800_REF19","doi-asserted-by":"crossref","unstructured":"Visani G, Finelli C, Castelli U, et al. Myelofibrosis with myeloid metaplasia: clinical and haematological parameters predicting survival in a series of 133 patients. Br J Haematol. 1990;75: 4-9.","DOI":"10.1111\/j.1365-2141.1990.tb02609.x"},{"key":"2020021218061268800_REF20","doi-asserted-by":"crossref","unstructured":"Barosi G, Berzuini C, Liberato LN, Costa A, Polino G, Ascari E. A prognostic classification of myelofibrosis with myeloid metaplasia. Br J Haematol. 1988;70: 397-401.","DOI":"10.1111\/j.1365-2141.1988.tb02507.x"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/105\/3\/973\/1706090\/zh800305000973.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/105\/3\/973\/1706090\/zh800305000973.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,13]],"date-time":"2020-02-13T00:08:09Z","timestamp":1581552489000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/105\/3\/973\/19627\/Leukemic-transformation-in-myelofibrosis-with"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,2,1]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,2,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2004-07-2864","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,2,1]]}}}